Alzheimer’s Drugs Market By Drug Class and Distribution Channel - Global Industry Analysis And Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC101402
Alzheimer’s Drugs Market By Drug Class (Combined Drug, Memantine, Cholinergic and Other Drug Class) and Distribution Channel (Online Sales, Retail Pharmacy and Hospital Pharmacy) - Global Industry Analysis And Forecast To 2027
Industry Outlook
Alzheimer's is a kind of dementia which causes issues with thinking, behavior and memory of the person suffering. Indications for the most part grow gradually and deteriorate after some time, getting to be sufficiently serious to hinder the day to day tasks. The Alzheimer's ailment is given the name after Dr. Alois Alzheimer. Dr. Alzheimer saw changes in the tissue of brain of a lady who died due to an uncommon psychological illness. The side effects she showed included language problems, memory loss, and an unpredictable behavior. The use of drugs for treating Alzheimer’s is growing due to increasing number of cases related to the disease, rising awareness amongst the population across the globe for treatment procedure of the disease, etc. Therefore, the Alzheimer’s Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Alzheimer’s Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.
Market Segmentation
On the basis of Drug Class, the market is further divided into Combined Drug, Memantine, Cholinergic and Other Drug Class. The section Memantine is leading the market due to factors like; long term expiry of patents related to main products, less numbers of medicines to for Alzheimer’s disorders treatment, etc.
On the basis of Distribution Channel, the market is further divided into Online Sales, Retail Pharmacy and Hospital Pharmacy. The Hospital Pharmacy section is dominating the market owing to rising demand from the people for disease treatment, rise in the number of people admitted to hospital for treatment, etc.
Regional Insights
The North American region is leading the global Alzheimer’s Drugs Market owing to factors like; huge number of the population suffering from this disease, rising awareness amongst the local population about the disease treatment options available, etc.
Alzheimer’s Drugs Market, By Region
-
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.
- Merz Holding GmbH & Co KG
- H Lundbeck A/S
- Novartis AG
- Ono Pharmaceutical
- Allergan plc
- Johnson & Johnson
- Daiichi Sankyo Company Limited
- Eisai Co Ltd.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
o Alzheimer’s Drugs Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
o Combined Drug
o Memantine
o Cholinergic
o Other Drug Class
o Alzheimer’s Drugs Market, By Distribution Channel, Estimates and Forecast, 2017-2027 ($Million)
o Online Sales
o Retail Pharmacy
o Hospital Pharmacy
o Alzheimer’s Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Alzheimer’s Drugs Market , By Country
o U.S. Alzheimer’s Drugs Market
o Canada Alzheimer’s Drugs Market
o Mexico Alzheimer’s Drugs Market
o Europe
§ Europe Alzheimer’s Drugs Market , By Country
o Germany Alzheimer’s Drugs Market
o UK Alzheimer’s Drugs Market
o France Alzheimer’s Drugs Market
o Russia Alzheimer’s Drugs Market
o Italy Alzheimer’s Drugs Market
o Rest of Europe Alzheimer’s Drugs Market
o Asia-Pacific
§ Asia-Pacific Alzheimer’s Drugs Market , By Country
o China Alzheimer’s Drugs Market
o Japan Alzheimer’s Drugs Market
o South Korea Alzheimer’s Drugs Market
o India Alzheimer’s Drugs Market
o Southeast Asia Alzheimer’s Drugs Market
o Rest of Asia-Pacific Alzheimer’s Drugs Market
o South America
§ South America Alzheimer’s Drugs Market , By Country
o Brazil Alzheimer’s Drugs Market
o Argentina Alzheimer’s Drugs Market
o Columbia Alzheimer’s Drugs Market
o Rest of South America Alzheimer’s Drugs Market
o Middle East and Africa
§ Middle East and Africa Alzheimer’s Drugs Market , By Country
o Saudi Arabia Alzheimer’s Drugs Market
o UAE Alzheimer’s Drugs Market
o Egypt Alzheimer’s Drugs Market
o Nigeria Alzheimer’s Drugs Market
o South Africa Alzheimer’s Drugs Market
o Rest of MEA Alzheimer’s Drugs Market
Table of Contents:
Chapter 1. Introduction
1.1. Report Description
Chapter 2. Executive Summary
2.1. Key Highlights
Chapter 3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
Chapter 4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
Chapter 5. Alzheimer’s Drugs Market, By Drug Class
5.1. Introduction
5.2. Global Alzheimer’s Drugs Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Alzheimer’s Drugs Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Combined Drug
5.3.1. Global Combined Drug Revenue and Growth Rate (2017-2027)
5.4. Memantine
5.4.1. Global Memantine Revenue and Growth Rate (2017-2027)
5.5. Cholinergic
5.5.1. Global Cholinergic Revenue and Growth Rate (2017-2027)
5.6. Other Drug Class
5.6.1. Global Other Drug Class Revenue and Growth Rate (2017-2027)
Chapter 6. Alzheimer’s Drugs Market, By Distribution Channel
6.1. Introduction
6.2. Global Alzheimer’s Drugs Revenue and Market Share by Distribution Channel (2017-2027)
6.2.1. Global Alzheimer’s Drugs Revenue and Revenue Share by Distribution Channel (2017-2027)
6.3. Online Sales
6.3.1. Global Online Sales Revenue and Growth Rate (2017-2027)
6.4. Retail Pharmacy
6.4.1. Global Retail Pharmacy Revenue and Growth Rate (2017-2027)
6.5. Hospital Pharmacy
6.5.1. Global Hospital Pharmacy Revenue and Growth Rate (2017-2027)
Chapter 7. Alzheimer’s Drugs Market, By Region
7.1. Introduction
7.2. Global Alzheimer’s Drugs Revenue and Market Share by Regions
7.2.1. Global Alzheimer’s Drugs Revenue by Regions (2017-2027)
7.3. North America Alzheimer’s Drugs by Countries
7.3.1. North America Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Alzheimer’s Drugs by Countries
7.4.1. Europe Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Alzheimer’s Drugs by Countries
7.5.1. Asia-Pacific Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Alzheimer’s Drugs by Countries
7.6.1. South America Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Alzheimer’s Drugs by Countries
7.7.1. Middle East and Africa Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Chapter 8. Company Profiles
8.1. Merz Holding GmbH & Co KG
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. H Lundbeck A/S
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Novartis AG
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Ono Pharmaceutical
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. Allergan plc
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. Johnson & Johnson
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Daiichi Sankyo Company Limited
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. Eisai Co Ltd.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
Chapter 9. Global Alzheimer’s Drugs Market Competition, by Manufacturer
9.1. Global Alzheimer’s Drugs Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Alzheimer’s Drugs Price By Region (2017-2017)
9.3. Top 5 Alzheimer’s Drugs Manufacturer Market Share
9.4. Market Competition Trend
Chapter 10. Alzheimer’s Drugs Market Forecast (2017-2027)
10.1. Global Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Alzheimer’s Drugs Market Forecast by Regions (2017-2027)
10.2.1. North America Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.1.1. United States Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.1.2. Canada Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.1.3. Mexico Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2. Europe Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.1. Germany Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.2. France Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.3. UK Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.4. Russia Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.5. Italy Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3. Asia-Pacific Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.1. China Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.2. Japan Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.3. Korea Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.4. India Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.4. South America Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.4.1. Brazil Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.4.2. Argentina Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.4.3. Columbia Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.4.4. Rest of South America Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5. Middle East and Africa Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.3. Egypt Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.4. Nigeria Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.5. South Africa Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.6. Turkey Alzheimer’s Drugs Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Alzheimer’s Drugs Market Forecast (2017-2027)
10.3. Alzheimer’s Drugs Market Forecast by Drug Class (2017-2027)
10.3.1. Alzheimer’s Drugs Forecast by Drug Class (2017-2027)
10.3.2. Alzheimer’s Drugs Market Share Forecast by Drug Class (2017-2027)
10.4. Alzheimer’s Drugs Market Forecast by Distribution Channel (2017-2027)
10.4.1. Alzheimer’s Drugs Forecast by Distribution Channel (2017-2027)
10.4.2. Alzheimer’s Drugs Market Share Forecast by Distribution Channel (2017-2027)
List of Tables and Figures:
Figure United States Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Alzheimer’s Drugs Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Alzheimer’s Drugs Revenue and Revenue Share by Drug Class (2017-2027)
Figure Global Combined Drug Revenue and Growth Rate (2017-2027)
Figure Global Memantine Revenue and Growth Rate (2017-2027)
Figure Global Cholinergic Revenue and Growth Rate (2017-2027)
Figure Global Other Drug Class Revenue and Growth Rate (2017-2027)
Table Global Alzheimer’s Drugs Revenue and Revenue Share by Distribution Channel (2017-2027)
Figure Global Online Sales Revenue and Growth Rate (2017-2027)
Figure Global Retail Pharmacy Revenue and Growth Rate (2017-2027)
Figure Global Hospital Pharmacy Revenue and Growth Rate (2017-2027)
Table Global Alzheimer’s Drugs Revenue by Regions (2017-2027)
Figure North America Alzheimer’s Drugs Growth Rate (2017-2027)
Figure North America Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
Figure North America Alzheimer’s Drugs by Countries (2017-2027)
Figure North America Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
Figure United States Alzheimer’s Drugs Growth Rate (2017-2027)
Figure United States Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Canada Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Canada Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Mexico Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Mexico Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Europe Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Europe Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
Figure Europe Alzheimer’s Drugs by Countries (2017-2027)
Figure Europe Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
Figure Germany Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Germany Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure France Alzheimer’s Drugs Growth Rate (2017-2027)
Figure France Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure UK Alzheimer’s Drugs Growth Rate (2017-2027)
Figure UK Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Russia Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Russia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Italy Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Italy Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Europe Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Rest of Europe Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Asia-Pacific Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Asia-Pacific Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
Figure Asia-Pacific Alzheimer’s Drugs by Countries (2017-2027)
Figure Asia-Pacific Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
Figure China Alzheimer’s Drugs Growth Rate (2017-2027)
Figure China Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Japan Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Japan Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Korea Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Korea Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure India Alzheimer’s Drugs Growth Rate (2017-2027)
Figure India Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Southeast Asia Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Southeast Asia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South America Alzheimer’s Drugs Growth Rate (2017-2027)
Figure South America Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
Figure South America Alzheimer’s Drugs by Countries (2017-2027)
Figure South America Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
Figure Brazil Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Brazil Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Argentina Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Argentina Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Columbia Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Columbia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of South America Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Rest of South America Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Middle East and Africa Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Middle East and Africa Alzheimer’s Drugs Revenue and Growth Rate (2017-2027)
Figure Middle East and Africa Alzheimer’s Drugs by Countries (2017-2027)
Figure Middle East and Africa Alzheimer’s Drugs Revenue (Million USD) by Countries (2017-2027)
Figure Saudi Arabia Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Saudi Arabia Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Alzheimer’s Drugs Growth Rate (2017-2027)
Figure United Arab Emirates Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Egypt Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Egypt Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Nigeria Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Nigeria Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure South Africa Alzheimer’s Drugs Growth Rate (2017-2027)
Figure South Africa Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Turkey Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Turkey Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Alzheimer’s Drugs Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Table Merz Holding GmbH & Co KG Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table H Lundbeck A/S Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Ono Pharmaceutical Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Allergan plc Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Johnson & Johnson Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Daiichi Sankyo Company Limited Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Eisai Co Ltd. Alzheimer’s Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Alzheimer’s Drugs Market Share by Manufacturer
Figure Global Alzheimer’s Drugs Revenue and Market Share by Manufacturer
Table Global Alzheimer’s Drugs Price by Region (2017-2017)
Figure Top 5 Alzheimer’s Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Alzheimer’s Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
Table Alzheimer’s Drugs Market Forecast by Regions (2017-2027)
Figure North America Alzheimer’s Drugs Market Forecast (2017-2027)
Figure United States Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Canada Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Mexico Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Europe Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Germany Alzheimer’s Drugs Market Forecast (2017-2027)
Figure France Alzheimer’s Drugs Market Forecast (2017-2027)
Figure UK Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Russia Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Italy Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Rest of Europe Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Asia-Pacific Alzheimer’s Drugs Market Forecast (2017-2027)
Figure China Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Japan Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Korea Alzheimer’s Drugs Market Forecast (2017-2027)
Figure India Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Southeast Asia Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Rest of Asia-Pacific Alzheimer’s Drugs Market Forecast (2017-2027)
Figure South America Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Brazil Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Argentina Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Columbia Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Rest of South America Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Middle East and Africa Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Saudi Arabia Alzheimer’s Drugs Market Forecast (2017-2027)
Figure United Arab Emirates Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Egypt Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Nigeria Alzheimer’s Drugs Market Forecast (2017-2027)
Figure South Africa Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Turkey Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Rest of Middle East and Africa Alzheimer’s Drugs Market Forecast (2017-2027)
Figure Global Alzheimer’s Drugs Forecast by Drug Class (2017-2027)
Figure Global Alzheimer’s Drugs Market Share Forecast by Drug Class (2017-2027)
Figure Global Alzheimer’s Drugs Forecast by Drug Class (2017-2027)
Figure Global Alzheimer’s Drugs Forecast by Distribution Channel (2017-2027)
Figure Global Alzheimer’s Drugs Market Share Forecast by Distribution Channel (2017-2027)
Figure Global Alzheimer’s Drugs Forecast by Distribution Channel (2017-2027)
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|